Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Austrian doctors oppose hospital outpatient fee removal

This article was originally published in Clinica

Executive Summary

Calls to remove hospital outpatient treatment fees (Ambulanzgebuhr), payable by the patient and then reimbursed by the sickness funds, have been rejected out of hand by the Austrian doctors' chamber (OAK). The Ambulanzgebuhr, which amounts to Sch250 ($16) or Sch150 with a GP referral per case, was introduced by the federal government in April, in an effort to control the number of patients seeking treatment in hospitals. "We had hoped that the introduction of such a measure would encourage people to opt for treatment from a GP, as this would save money for both the patient and the social state," a spokesperson for the ministry of health told Clinica.

You may also be interested in...



MoCRA Stakeholders Reminded Registration Enforcement Begins 1 July: ‘Do Not Delay!’

The Independent Beauty Association urged stakeholders at its Cosmetic Convergence Symposium to take action to ensure they are meeting requirements of the Modernization of Cosmetics Regulation Act come 1 July, when FDA’s enforcement of the facility and product registration deadline begins. Presenters offered tips from companies that have already completed the process.

Boehringer Ingelheim Overtakes Bayer As Germany’s Biggest Pharma Company

The privately owned company is searching for a successor to Jardiance, while the outcome of US Inflation Reduction Act talks on price cuts to the blockbuster will be revealed in September.

Synthekine Joins Quest To Tame IL-2 In Cancer Therapies

First clinical data from Synthekine’s IL-2 candidate and that ofrivalsMedicennawere presented at the AACR, suggesting there’s life in the modality yet.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT072424

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel